Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 1, 2013, Pages 12-18

  Zeisler, Bella ^a   Lerer, Trudy ^a   Markowitz, James ^b   MacK, David ^c   Griffiths, Anne ^d   Bousvaros, Athos ^e   Keljo, David ^f   Rosh, Joel ^g   Evans, Jonathan ^h   Kappelman, Michael ⁱ   Otley, Anthony ^j   Kay, Marsha ^k   Grossman, Andrew ^l   Saeed, Shehzad ^m   Carvalho, Ryan ⁿ   Oliva Hemker, Maria ^o   Faubion, William ^p   Sudel, Boris ^q   Pfefferkorn, Marian ^r   Ashai Khan, Farhat ^s   Leleiko, Neal ^t   Hyams, Jeffrey ^a   more..

^a Division of Pediatric Infectious Diseases   (United States)

^b Northwell Health   (United States)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g Goryeb Children's Hospital   (United States)

^h NEMOURS CHILDREN S CLINIC   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j IWK HEALTH CENTRE   (Canada)

^k LERNER RESEARCH INSTITUTE   (United States)

^l CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^m Children's Medical Center   (United States)

ⁿ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^o JOHNS HOPKINS HOSPITAL   (United States)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF MINNESOTA   (United States)

^r RILEY HOSPITAL FOR CHILDREN   (United States)

^s CHILDREN S MEDICAL CENTER   (United States)

^t HASBRO CHILDREN'S HOSPITAL   (United States)

more..

Author keywords

5 aminosalicylate; children; ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; AZATHIOPRINE; CYCLOSPORIN; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TACROLIMUS;

ABDOMINAL PAIN; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COLON RESECTION; DEMOGRAPHY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSURIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE PRICING; RASH; REMISSION; SCHOOL CHILD; THROMBOCYTE COUNT; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84872290627     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31826ac41a     Document Type: Article

References (33)

1. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544.
2. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(3):CD000543.
3. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastro-enterol 2011;106:601-16.
4. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993;17:32-8.
5. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81-8.
6. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005;21:1111-9.
7. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995;7:1025-30.
8. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-16.
9. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-86.
10. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800mg tablets) compared to 2.4 g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21:827-34.
11. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85.
12. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001;7:237-42.
13. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, doseranging study. Aliment Pharmacol Ther 2006;24:1087-97.
14. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009;30:908-18.
15. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-9.
16. Hommel KA, Herzer M, Ingerski LM, et al. Individually tailored treatment of medication nonadherence: A pilot study. J Pediatr Gastro-enterol Nutr 2011;53:435-9.
17. Hommel KA, Denson LA, Baldassano RN. Oral medication adherence and disease severity in pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23:250-4.
18. Ingerski LM, Baldassano RN, Denson LA, et al. Barriers to oral medication adherence for adolescents with inflammatory bowel disease. J Pediatr Psychol 2010;35:683-91.
19. Hommel KA, Denson LA, Crandall WV, et al. Behavioral Functioning and treatment adherence in pediatric inflammatory bowel disease: review and recommendations for practice. Gastroenterol Hepatol (N Y) 2008;4:785.
20. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996;38:229-33.
21. Cortot A, Maetz D, Degoutte E, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008;103:3106-14.
22. Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996;91:1338-42.
23. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999;13:381-8.
24. Piodi LP, Ulivieri FM, Cermesoni L, et al. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004;39:154-7.
25. Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with highdose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994;37:58-62.
26. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009; 15:1218-23.
27. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1081-8.
28. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
29. Turner D, Griffiths AM, Mack D, et al. Assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis 2010;16:651-6.
30. Fazio VW, Tekkis PP, Remzi F, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg 2003;238:605-14.
31. Moore JC, Thompson K, Lafleur B, et al. Clinical variables as prognostic tools in pediatric-onset ulcerative colitis: a retrospective cohort study. Inflamm Bowel Dis 2011;17:15-21.
32. Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med 2010; 122:177-85.
33. Anderson CA, Boucher G, Lees CW, et al. Corrigendum: meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:919.